Advancing Research in CKD with Briya’s Dynamic Datasets

Chronic Kidney Disease (CKD) impacts an estimated 850 million people worldwide and is the seventh leading cause for mortality. Early detection of CKD remains a challenge due to the disease’s often asymptomatic nature in its initial stages. Current diagnostic practices rely heavily on blood and urine tests to measure critical biomarkers such as albuminuria, serum creatinine, and glomerular filtration rate (GFR)—key indicators for assessing CKD risk and progression.

Briya’s CKD Dynamic Dataset bridges critical gaps in CKD research by offering a comprehensive, real-world dataset tailored to the complexities of the disease. Designed to create a complete picture from fragmented data across departments, this standardized, and compliant dataset, empowers researchers to accelerate breakthroughs, optimize treatments, and transform patient outcomes. Covering 31,000 patient records, it provides a rich spectrum of data, including CKD staging (1-5), kidney function metrics (GFR, Serum Creatinine, BUN), lab panels for electrolytes, hemoglobin, and calcium-phosphate metabolism, as well as urinalysis, imaging, and genetic tests. The dataset also integrates unique insights like kidney biopsy results, cardiovascular measures (ECG, vascular ultrasound), and dialysis-related metrics for patients undergoing treatment.

With Briya, CKD insights are within reach.